Waters Corporation (WAT)
| Market Cap | 36.76B |
| Revenue (ttm) | 3.77B |
| Net Income (ttm) | 449.63M |
| Shares Out | 98.19M |
| EPS (ttm) | 6.89 |
| PE Ratio | 54.37 |
| Forward PE | 24.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,032,520 |
| Open | 377.94 |
| Previous Close | 376.89 |
| Day's Range | 369.44 - 379.73 |
| 52-Week Range | 275.05 - 414.15 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 401.78 (+7.31%) |
| Earnings Date | Aug 3, 2026 |
About WAT
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, p... [Read more]
Financial Performance
In 2025, Waters's revenue was $3.17 billion, an increase of 6.99% compared to the previous year's $2.96 billion. Earnings were $642.63 million, an increase of 0.75%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for WAT stock is "Buy." The 12-month stock price target is $401.78, which is an increase of 7.31% from the latest price.
News
Waters resumed with an Outperform at Bernstein
Bernstein analyst Eve Burstein resumed coverage of Waters (WAT) with an Outperform rating and $435 price target following a return from maternity leave. “Many things” are going right for the…
IMU Biosciences, Waters announce strategic partnership
IMU Biosciences and Waters (WAT) Corporation announced a strategic partnership to accelerate the development of IMU’s next-generation AI-powered High Definition Immunology platform. The partnership br...
Waters and IMU Biosciences announce strategic partnership
Waters (WAT) and IMU Biosciences, a biotechnology company decoding the immune system, announced a strategic partnership to accelerate the development of IMU’s next-generation AI-powered High Definitio...
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
LONDON--(BUSINESS WIRE)--IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, and Waters Corporation (NYSE...
Waters initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of Waters (WAT) with a Neutral rating and $400 price target The firm launched coverage of the life science tools sector with a “feet in the…
Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis
Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway. Unique whole-cell design eliminates cell teardown, reducing samp...
Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks. Delivers up to 2x increase in resolving powe...
Waters Transcript: Jefferies Global Healthcare Conference 2026
Double-digit growth was driven by new products, recurring revenue, and strong pharma performance, especially in China and India. Integration efforts are yielding commercial and operational synergies, with accelerated product launches and localization supporting future gains. Pricing improvements and innovation in mass spectrometry and antibodies are set to drive continued growth.
Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% ...
Waters price target raised to $435 from $415 at HSBC
HSBC raised the firm’s price target on Waters (WAT) to $435 from $415 and keeps a Buy rating on the shares. The firm says market expectations on life science tools…
Waters price target raised to $400 from $370 at BofA
BofA raised the firm’s price target on Waters (WAT) to $400 from $370 and keeps a Neutral rating on the shares. Diagnostic tools have rallied almost 10% in the last…
Waters assumed with an Outperform at Wolfe Research
Wolfe Research assumed coverage of Waters (WAT) with an Outperform rating and $425 price target The firm stated in a research note on Life Science Tools & Diagnostics that the…
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Ide...
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease sign...
Waters Corporation to Present at the Jefferies Global Healthcare Conference
MILFORD, Mass., May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Waters price target raised to $350 from $330 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Waters (WAT) to $350 from $330 and keeps a Hold rating on the shares.
Waters price target raised to $425 from $400 at Barclays
Barclays raised the firm’s price target on Waters (WAT) to $425 from $400 and keeps an Overweight rating on the shares. The firm updated the company’s model post the earnings…
Waters price target raised to $387 from $362 at Baird
Baird raised the firm’s price target on Waters (WAT) to $387 from $362 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results. Published…
Waters price target raised to $345 from $330 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Waters (WAT) to $345 from $330 and keeps a Neutral rating on the shares.
Waters price target raised to $385 from $345 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Waters (WAT) to $385 from $345 and keeps a Hold rating on the shares. The firm updated its model…
Waters price target raised to $375 from $330 at UBS
UBS raised the firm’s price target on Waters (WAT) to $375 from $330 and keeps a Neutral rating on the shares.
Waters CEO highlights China as key innovation source in the biopharma market
Waters CEO Udit Batra highlighted China as a global biopharmaceutical powerhouse. He said that innovation has fueled a rapid expansion of contract manufacturers moving into full drug development.
Waters raises annual profit forecast as biosciences unit drives growth
Lab equipment maker Waters raised its annual profit forecast on Tuesday after beating quarterly estimates, driven by robust demand for drug development tools and the strong performance of its biosci...
Waters Earnings Call Transcript: Q1 2026
Strong Q1 performance with double-digit organic growth, robust execution in acquired businesses, and 20% adjusted EPS growth led to raised 2026 revenue and EPS guidance. Integration and synergy realization are ahead of plan, with new product launches and China localization supporting future growth.
Waters Slides: Q1 2026
Waters has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.